Page 4 - Sclerosis Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022.NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough...

- Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response - FDA allows for continued enrollment under

The funds will support clinical and basic medical research under Dr. Rhonda Voskuhl, director of the UCLA Multiple Sclerosis Program.

COVID-19 pandemic has created major changes in delivery of MS care A survey of U.S. multiple sclerosis, or MS, specialist clinicians reveals the COVID-19 pandemic has created major changes in how they deliver care. "Since the pandemic began, more than 95% of our survey respondents reported using telehealth platforms to provide care for their patients," said Dr. Elizabeth Morrison-Banks, a health sciences clinical professor of neurology in the School of Medicine at the University of California, Riverside, who led the survey reported in the journal Multiple Sclerosis and Related Disorders. "Ap...

 E-Mail IMAGE: Dr. Elizabeth Morrison-Banks is a health sciences clinical professor of neurology at UC Riverside. view more  Credit: C. Rosema. RIVERSIDE, Calif. -- A survey of U.S. multiple sclerosis, or MS, specialist clinicians reveals the COVID-19 pandemic has created major changes in how they deliver care. "Since the pandemic began, more than 95% of our survey respondents reported using telehealth platforms to provide care for their patients," said Dr. Elizabeth Morrison-Banks, a health sciences clinical professor of neurology in the School of Medicine at the University of Cali...